This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Galaxy Biotech, LLC

Drug Names(s): TAK-701

Description: HuL2G7 is a recombinant, humanized antibody that blocks the activity of human Hepatocyte Growth Factor (HGF), a growth factor believed to mediate proliferation, metastasis,anti-apoptosis and neoangiogenesis of many types of tumors.

Deal Structure: In July 2006, Takeda signed a licensing agreement with Galaxy Biotech for HuL2G7. Under the agreement, Takeda is licensed to exclusively develop, manufacture, and sell HuL2G7 worldwide. Takeda Pharmaceutical will make an upfront payment of $2 million, milestone payments on future development and royalties on product sales.

In July 2012, Takeda returned all rights to HuL2G7 to Galaxy.

HuL2G7 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug